Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novavax and Takeda Pharmaceutical Company announced a partnership for the development, manufacturing and commercialization of NVX-CoV2373 in Japan. Takeda will…
Novavax has expanded its license and manufacturing agreement with South Korea's SK Bioscience covering local production and commercialization of…
The U.S. Food and Drug Administration today issued an emergency use authorization for the Novavax COVID-19 Vaccine, Adjuvanted, for the prevention of…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Novavax expanded its collaboration and license agreement with SK Bioscience for manufacture and commercialization of NVX-CoV2373 in South Korea, including a 40 million dose advance purchase agreement with the Korean government. Estimated ~$300M cumulative deal value across upfront, milestones and supply.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novavax Inc. / SK Bioscience Co., Ltd. (this deal) | 2021 | $300M | — |
| Novavax Inc. / Praha Vaccines | 2020 | $167M | 48 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) | 2014 | $635M | 77 |
| GSK plc / Affinivax Inc. | 2022 | $3.3B | 48 |
| Johnson & Johnson / Crucell N.V. | 2010 | $2.4B | 47 |
← Browse all deals · How we score deals
More: 2021 deals · Vaccines deals